What is Royalty Pharma's accounts payable?

Royalty Pharma (RPRX) reported accounts payable of $25.48M in Q1 2026.

How has Royalty Pharma's accounts payable changed year-over-year?

Royalty Pharma's accounts payable decreased by 32.3% year-over-year, from $37.63M to $25.48M.

What is the long-term trend for Royalty Pharma's accounts payable?

Over 5 years (2020 to 2025), Royalty Pharma's accounts payable has grown at a 12.5% compound annual growth rate (CAGR), from $10.78M to $19.4M.

What does accounts payable mean?

Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Royalty Pharma RPRX Accounts Payable

Accounts Payable at other companies

Ligand PharmaceuticalsLGND

$5.26M-1.9%

BridgeBio PharmaBBIO

$29.06M+5.6%

Rigel PharmaceuticalsRIGL

$4.49M+13.5%

Roivant SciencesROIV

$18M-24.0%

Ionis PharmaceuticalsIONS

$47.7M+109%

Bristol-Myers SquibbBMY

$4.16B-23.4%

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's accounts payable?: Royalty Pharma (RPRX) reported accounts payable of $25.48M in Q1 2026.
How has Royalty Pharma's accounts payable changed year-over-year?: Royalty Pharma's accounts payable decreased by 32.3% year-over-year, from $37.63M to $25.48M.
What is the long-term trend for Royalty Pharma's accounts payable?: Over 5 years (2020 to 2025), Royalty Pharma's accounts payable has grown at a 12.5% compound annual growth rate (CAGR), from $10.78M to $19.4M.
What does accounts payable mean?: Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.